Dr. Grob's clinical interests include mood and anxiety disorders, as well as the self-medication hypothesis of substance abuse as it applies to substance abuse. His research has included the first FDA approved Phase 1 study of the physiological and psychological effects of MDMA (3,4-methlyenedioxymethamphetamine), a multi-national, collaborative study of the Amazonian plant hallucinogen decoction, ayahuasca, in Brazil and a pilot investigation of the safety and efficacy of psilocybin in the treatment of anxiety in adult patients with advanced-stage cancer. His most recent research has examined the safety and efficacy of an MDMA treatment model with adult autistics with severe social anxiety.
MD, 1979, State University of New York, Downstate Medical Center, Brooklyn, NY
Recent and/or Significant Publications
Grob, C.S, Danforth, A.L, Chopra, G.S, Hagerty, M.C, McKay, C.R, Halberstadt, A.L. and Greer, G.R. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry 68:71-78, 2011.
Grob, C.S, Bossis, A.P. and Griffiths, R.R. Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer: in B. Carr and J. Steel (Eds.), Psychological Aspects of Cancer. New York, Springer, pp. 291-308, 2013.
Danforth, A.L, Struble, C.M, Yazar-Klosinski, B. and Grob, C.S. MDMA-assisted therapy: a new treatment model for social anxiety in autistic adults. Progress in Neuropsychopharmacology and Biological Psychiatry, 64:237-249, 2016.